Extension Study Will Continue Evaluating Oral Edaravone

Extension Study Will Continue Evaluating Oral Edaravone

281907

Extension Study Will Continue Evaluating Oral Edaravone

Mitsubishi Tanabe Pharma America (MTPA) has launched an extension study to assess the long-term effects of an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis (ALS). “As a company, we strive to always put patients first in our efforts to understand this debilitating disease. We hope this extension study will help provide important information to the ALS community,” Atsushi Fujimoto, president of MTPA, said in a press release. This open-label…

You must be logged in to read/download the full post.